Aqueous hydrocortisone mouthwash solution: clinical evaluation.
Patients often experience difficulties in applying topical steroids in orabase to the oral mucosa, particularly when large areas need to be covered. An aqueous hydrocortisone mouthwash solution has been developed, one that was anticipated to be more acceptable to patients. The solution contains hydrocortisone (0.3% w/v) in a 4.5% (w/v) 2-hydroxypropyl-beta-cyclodextrin solution. Hydroxypropylmethylcellulose (0.5% w/v) was used to increase the viscosity of the solution and to promote the hydrocortisonecyclodextrin complex. One hundred and two patients with aphthous ulceration, lichen planus, and other mucosal conditions used the mouthwash in an open clinical efficacy study. Most patients reported some or considerable improvement following a 2-week course of treatment with the mouthwash: 26 of 33 (78.8%) patients with aphthous ulceration were 'much better', as were 26 of 54 (48.1%) patients with lichen planus and 5 of 16 (31.3%) patients with other mucosal lesions. No serious side effects were reported. Aqueous mouthwash solutions offer a potential vehicle for topical steroid therapy of oral mucosal lesions.
Holbrook
W P
WP
Faculty of Odontology and Department of Pharmacy, University of Iceland, Reykjavík.
Kristmundsdóttir
T
T
Loftsson
T
T
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D002614:Chelating Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D002648:Child; D003505:Cyclodextrins / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D005079:Excipients; D005260:Female; D006801:Humans; D006854:Hydrocortisone; D065347:Hypromellose Derivatives; D017676:Lichen Planus, Oral / Q000188:drug therapy; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy*; D009061:Mouth Mucosa / Q000187:drug effects; D009067:Mouthwashes / Q000737:chemistry / Q000627:therapeutic use*; D010592:Pharmaceutic Aids; D014677:Pharmaceutical Vehicles; D012074:Remission Induction; D013281:Stomatitis, Aphthous / Q000188:drug therapy; D016896:Treatment Outcome; D014783:Viscosity; D047392:beta-Cyclodextrins
D000893:Anti-Inflammatory Agents; D002614:Chelating Agents; D003505:Cyclodextrins; D005079:Excipients; D009067:Mouthwashes; D010592:Pharmaceutic Aids; D014677:Pharmaceutical Vehicles; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D065347:Hypromellose Derivatives; D008747:Methylcellulose; D006854:Hydrocortisone